Latest Janssen Biotech Inc. Stories
Data Show 84% Progression-Free Survival Rate at One Year and Improvement in Quality of Life SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc.
- Note: This press release corresponds to abstracts 627 and 1998. SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced by Pharmacyclics, Inc.
- Note: This press release corresponds to abstract 31. SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA(®) (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc.
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
LONDON, SUNNYVALE, Calif. and RARITAN, N.J., Nov.
"Get Your Full Course" addresses diet and nutritional considerations related to inflammatory bowel diseases and highlights Sunny's personal story of living with ulcerative colitis HORSHAM,
Approval based on Phase 3 RESONATE data with statistically significant improvements in progression-free and overall survival HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S.
Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits SUNNYVALE, Calif., July 28, 2014 /PRNewswire/ -- Pharmacyclics,
CAMBRIDGE, Mass., June 24, 2014 /PRNewswire/ -- Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc.
Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus
- A person or thing gazed at with wonder or curiosity, especially of a scornful kind.